Bhumsuk Keam

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

March, 2025

Bhumsuk Keam

Aug 22, 2024, 14:00 | Insight

Jarushka Naidoo: Phase II Lazertinib in EGFR+ NSCLC with CNS disease

Jarushka Naidoo shared a post on X: “Phase II Lazertinib in EGFR+ NSCLC with CNS disease,…

Aug 21, 2024, 08:20 | Insight

5 articles suggested by Vivek Subbiah

Vivek Subbiah shared a few must-reads paper on X: 1. Dose selection of novel anticancer…

Jul 10, 2024, 02:17 | Blog

Biagio Ricciuti: Resistance mechanisms in insertion-mutant NSCLC

Biagio Ricciuti shared on X: "Resistance mechanisms to EGFR TKIs in EGFR ex 20 insertion-mutant NSCLC:…

All: 3 Posts: 1 - 100

'

Karen Knudsen has been appointed as the CEO of the Parker Institute for Cancer Immunotherapy

'

Highlights from ELCC 2025

'

FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer

'

Meet the New AACR Board of Directores for 2025-2028 Term

'

Do Artificial Sweeteners Cause Cancer? Myths and Facts

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023